The S100B Protein: A Multifaceted Pathogenic Factor More Than a Biomarker

被引:66
作者
Michetti, Fabrizio [1 ,2 ,3 ,4 ]
Clementi, Maria Elisabetta [5 ]
Di Liddo, Rosa [6 ]
Valeriani, Federica [7 ]
Ria, Francesco [8 ]
Rende, Mario [9 ]
Di Sante, Gabriele [9 ]
Romano Spica, Vincenzo [7 ]
机构
[1] Univ Cattolica Sacro Cuore, Dept Neurosci, I-00168 Rome, Italy
[2] Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst, I-20132 Milan, Italy
[3] LUM Univ, Dept Med, I-70010 Casamassima, Italy
[4] Genes, Via Venti Settembre 118, I-00187 Rome, Italy
[5] Ist Sci & Tecnol Chim Giulio Natta SCITEC, CNR, I-00168 Rome, Italy
[6] Univ Padua, Dept Pharmaceut & Pharmacol Sci, I-35131 Padua, Italy
[7] Univ Rome Foro Italico, Dept Movement Human & Hlth Sci, Lab Epidemiol & Biotechnol, I-00135 Rome, Italy
[8] Univ Cattolica Sacro Cuore, Dept Translat Med & Surg, Sect Gen Pathol, I-00168 Rome, Italy
[9] Univ Perugia, Dept Med & Surg, Sect Human Clin & Forens Anat, I-06132 Perugia, Italy
关键词
S100B protein; pathogenic factor; TRAUMATIC BRAIN-INJURY; ARUNDIC ACID ONO-2506; DELAYED INFARCT EXPANSION; PERMANENT FOCAL ISCHEMIA; ASTROCYTIC ACTIVATION; CEREBROSPINAL-FLUID; PARKINSONS-DISEASE; THERAPEUTIC TARGET; ALZHEIMERS-DISEASE; CEREBRAL AMYLOIDOSIS;
D O I
10.3390/ijms24119605
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
S100B is a calcium-binding protein mainly concentrated in astrocytes in the nervous system. Its levels in biological fluids are recognized as a reliable biomarker of active neural distress, and more recently, mounting evidence points to S100B as a Damage-Associated Molecular Pattern molecule, which, at high concentration, triggers tissue reactions to damage. S100B levels and/or distribution in the nervous tissue of patients and/or experimental models of different neural disorders, for which the protein is used as a biomarker, are directly related to the progress of the disease. In addition, in experimental models of diseases such as Alzheimer's and Parkinson's diseases, amyotrophic lateral sclerosis, multiple sclerosis, traumatic and vascular acute neural injury, epilepsy, and inflammatory bowel disease, alteration of S100B levels correlates with the occurrence of clinical and/or toxic parameters. In general, overexpression/administration of S100B worsens the clinical presentation, whereas deletion/inactivation of the protein contributes to the amelioration of the symptoms. Thus, the S100B protein may be proposed as a common pathogenic factor in different disorders, sharing different symptoms and etiologies but appearing to share some common pathogenic processes reasonably attributable to neuroinflammation.
引用
收藏
页数:15
相关论文
共 148 条
[1]   Blood biomarkers predictive of epilepsy after an acute stroke event [J].
Abraira, Laura ;
Santamarina, Estevo ;
Cazorla, Sonia ;
Bustamante, Alejandro ;
Quintana, Manuel ;
Toledo, Manuel ;
Fonseca, Elena ;
Grau-Lopez, Laia ;
Jimenez, Marta ;
Ciurans, Jordi ;
Becerra, Juan Luis ;
Millan, Monica ;
Hernandez-Perez, Maria ;
Cardona, Pere ;
Terceno, Mikel ;
Zaragoza, Josep ;
Canovas, David ;
Gasull, Teresa ;
Ustrell, Xavier ;
Rubiera, Marta ;
Castellanos, Mar ;
Montaner, Joan ;
Alvarez-Sabin, Jose .
EPILEPSIA, 2020, 61 (10) :2244-2253
[2]   Serum S100B protein as a marker of severity in Covid-19 patients [J].
Aceti, Antonio ;
Margarucci, Lory Marika ;
Scaramucci, Elena ;
Orsini, Massimiliano ;
Salerno, Gerardo ;
Di Sante, Gabriele ;
Gianfranceschi, Gianluca ;
Di Liddo, Rosa ;
Valeriani, Federica ;
Ria, Francesco ;
Simmaco, Maurizio ;
Parnigotto, Pier Paolo ;
Vitali, Matteo ;
Romano Spica, Vincenzo ;
Michetti, Fabrizio .
SCIENTIFIC REPORTS, 2020, 10 (01)
[3]   S100B, GFAP, UCH-L1 and NSE as predictors of abnormalities on CT imaging following mild traumatic brain injury: a systematic review and meta-analysis of diagnostic test accuracy [J].
Amoo, Michael ;
Henry, Jack ;
O'Halloran, Philip J. ;
Brennan, Paul ;
Ben Husien, Mohammed ;
Campbell, Matthew ;
Caird, John ;
Javadpour, Mohsen ;
Curley, Gerard F. .
NEUROSURGICAL REVIEW, 2022, 45 (02) :1171-1193
[4]   Emerging role of S100B protein implication in Parkinson's disease pathogenesis [J].
Angelopoulou, Efthalia ;
Paudel, Yam Nath ;
Piperi, Christina .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2021, 78 (04) :1445-1453
[5]   Arundic Acid (ONO-2506) Ameliorates Delayed Ischemic Brain Damage by Preventing Astrocytic Overproduction of S100B [J].
Asano, T. ;
Mori, T. ;
Shimoda, T. ;
Shinagawa, R. ;
Satoh, S. ;
Yada, N. ;
Katsumata, S. ;
Matsuda, S. ;
Kagamiishi, Y. ;
Tateishi, N. .
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2005, 4 (02) :127-142
[6]   Treatment with the Neurotrophic Protein S100 Calcium-Binding Protein B Increases Synaptogenesis after Traumatic Brain Injury [J].
Baecker, Justus ;
Wartchow, Krista ;
Sehm, Tina ;
Ghoochani, Ali ;
Buchfelder, Michael ;
Kleindienst, Andrea .
JOURNAL OF NEUROTRAUMA, 2020, 37 (08) :1097-1107
[7]   Extracellular S100B inhibits A-type voltage-gated potassium currents and increases L-type voltage-gated calcium channel activity in dopaminergic neurons [J].
Bancroft, Eric A. ;
De La Mora, Martha ;
Pandey, Gauri ;
Zarate, Sara M. ;
Srinivasan, Rahul .
GLIA, 2022, 70 (12) :2330-2347
[8]   Blood biomarkers in epilepsy [J].
Banote, Rakesh Kumar ;
Akel, Sarah ;
Zelano, Johan .
ACTA NEUROLOGICA SCANDINAVICA, 2022, 146 (04) :362-368
[9]   S100B as a Potential Biomarker and Therapeutic Target in Multiple Sclerosis [J].
Barateiro, Andreia ;
Afonso, Vera ;
Santos, Gisela ;
Cerqueira, Joo Jos ;
Brites, Dora ;
van Horssen, Jack ;
Fernandes, Adelaide .
MOLECULAR NEUROBIOLOGY, 2016, 53 (06) :3976-3991
[10]   S100B inhibition protects from chronic experimental autoimmune encephalomyelitis [J].
Barros, Catarina ;
Barateiro, Andreia ;
Neto, Alexandre ;
Soromenho, Beatriz ;
Bastos, Afonso P. ;
Mateus, Joana M. ;
Xapelli, Sara ;
Sebastiao, Ana M. ;
Brites, Dora ;
Graca, Luis ;
Fernandes, Adelaide .
BRAIN COMMUNICATIONS, 2022, 4 (03)